Sign In
Buy ACRX
$0.86
+0 (+0%)
At Close: Apr 08, 2024
AcelRx Announces Rebranding With Name Change to Talphera, Inc.
09:05am, Tuesday, 09'th Jan 2024
Name change to "Talphera" reflects a new era of the Company in partnership with the medical community developing novel solutions for medically supervised settings Talphera will begin trading on Nasdaq
Use of CRRT increased during COVID and remained at these higher utilization levels Study results demonstrate challenges physicians have with heparin and citrate, the two currently available CRRT antic
AcelRx Pharmaceuticals, Inc. (ACRX) Q3 2023 Earnings Call Transcript
12:27am, Thursday, 09'th Nov 2023
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Raffi Asadorian - CFO Vince Angotti - CEO Pam Palmer - Chief Medical Offic
AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update
04:05pm, Wednesday, 08'th Nov 2023
Niyad™ Investigational Device Exemption (IDE) approval by the FDA achieved in third quarter Company plans to begin its Niyad registrational study this quarter with topline data expected mid-2024 Cas
AcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023
04:30pm, Thursday, 26'th Oct 2023
HAYWARD, Calif. , Oct. 26, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative
AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study
08:30am, Tuesday, 03'rd Oct 2023
Investigational Device Exemption (IDE) approval by the U.S. Food and Drug Administration (FDA) allows AcelRx to begin pivotal study of Niyad™ Single registration study with pre-agreed upon endpoints
AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference
08:30am, Wednesday, 06'th Sep 2023
SAN MATEO, Calif. , Sept. 6, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovati
What Makes AcelRx Pharmaceuticals (ACRX) a New Buy Stock
06:47pm, Tuesday, 22'nd Aug 2023
AcelRx Pharmaceuticals (ACRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AcelRx Pharmaceuticals, Inc. (ACRX) Q2 2023 Earnings Call Transcript
08:16pm, Thursday, 10'th Aug 2023
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Raffi Asadorian – Chief Financial Officer Vince Angotti – Chief Executi
AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Tops Revenue Estimates
07:01pm, Thursday, 10'th Aug 2023
AcelRx Pharmaceuticals (ACRX) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $1.20 per share a year ago.
AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update
04:05pm, Thursday, 10'th Aug 2023
Capital raise closed in July, led by new healthcare investors; provides access to up to $26.3 million in capital, with $10 million immediately available AcelRx awaits response to Emergency Use Authori
AcelRx to Host Second Quarter 2023 Financial Results Call and Webcast on August 10, 2023
04:05pm, Thursday, 27'th Jul 2023
HAYWARD, Calif. , July 27, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative
AcelRx Pharmaceuticals Announces Closing of Previously Announced Private Placement Priced At-The-Market Under Nasdaq Rules
08:00am, Friday, 21'st Jul 2023
Transformative capital raise, led by new investors including Nantahala Capital Management The private placement provides access to up to $26.3 million of gross proceeds upon the exercise of the mil
AcelRx Pharmaceuticals Announces $10 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
08:00am, Tuesday, 18'th Jul 2023
Upon the achievement of certain milestones accelerating the warrants' expiration date, AcelRx may receive an additional $16.3 million of gross proceeds if the common warrants are exercised in full HAY
AcelRx Pharmaceuticals (ACRX) Reports Break-Even Earnings for Q1
07:45pm, Wednesday, 10'th May 2023
AcelRx Pharmaceuticals (ACRX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.80. This compares to loss of $1.20 per share a year ago.
